Navid Heyrani's practice focuses on public and private M&A (both domestic and cross-border), corporate governance, and general corporate and securities matters.
Navid represents clients from a broad range of industries, including biopharmaceutical, medical device, pharmaceutical, technology, energy, telecommunications, and retail. Representative clients include Abbott Laboratories, Advantage Solutions, Ambry Genetics, Astellas Pharma US, the Internet Corporation for Assigned Names and Numbers (ICANN), Linear Technologies, Silver Chef Limited, Social Finance, Sumitomo Corporation, TDK Corporation, and Terumo Corporation.
Recent representations include Linear Technology's $14.8 billion sale to Analog Devices; TDK Corporation's $1.3 billion acquisition of InvenSense; Ambry Genetics' $1.0 billion sale to Konica Minolta; Advantage Solution's acquisitions of The Data Council, Quiverr Collective, and Upshot, Inc.; and ICANN in connection with the successful completion of the transition of the Internet Assigned Numbers Authority functions from the U.S. National Telecommunications and Information Administration to ICANN.
- University of California, Los Angeles (J.D. 2014; Managing Editor, Journal of International Law and Foreign Affairs; B.A. in History 2010; Pi Alpha Theta)